Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A planned registrational phase III trial of AE 37 in patients with breast cancer.

Trial Profile

A planned registrational phase III trial of AE 37 in patients with breast cancer.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AE 37 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 31 May 2013 This trial is being prepared as part of a Special Protocol Assessment (SPA) with the US FDA, according to a Generex Biotechnology Corporation media release.
  • 17 Jan 2013 Planned initiation date changed from 1 Jan 2013 to 1 Mar 2013; the FDA will accept submission of a phase III breast cancer trial protocol.
  • 03 Jan 2012 Planned initiation date changed from 1 Jun 2013 to 1 Jun 2012, according to a Generex media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top